Darolutamide

Generic Name
Darolutamide
Brand Names
Nubeqa
Drug Type
Small Molecule
Chemical Formula
C19H19ClN6O2
CAS Number
1297538-32-9
Unique Ingredient Identifier
X05U0N2RCO
Background

Darolutamide is a nonsteroidal androgen receptor antagonist for the treatment of castrate-resistant, non-metastatic prostate cancer (nmCRPC). This condition occurs in the majority of patients with advanced prostate cancer who have been treated with androgen receptor antagonists. Though prior treatment for prostate cancer has been successful for these patient...

Indication

Darolutamide is indicated for the treatment of adults with non-metastatic castration-resistant prostate cancer (nmCRPC) and metastatic hormone-sensitive prostate cancer (mHSPC) in combination with docetaxel.

Associated Conditions
Metastatic Hormone-Sensitive Prostate Cancer (mHSPC), Non-Metastatic Castration-Resistant Prostate Cancer
Associated Therapies
-

Androgen Receptor Directed Therapy on Cognitive Function in Patients Treated With Darolutamide or Enzalutamide

First Posted Date
2020-04-06
Last Posted Date
2024-08-07
Lead Sponsor
Alliance Foundation Trials, LLC.
Target Recruit Count
132
Registration Number
NCT04335682
Locations
🇺🇸

Northwestern University Feinberg School of Medicine, Chicago, Illinois, United States

🇺🇸

University of Chicago, Chicago, Illinois, United States

🇺🇸

Dana Farber Cancer Institute, Boston, Massachusetts, United States

and more 6 locations

Darolutamide + Consolidation Radiotherapy in Advanced Prostate Cancer Detected by PSMA

First Posted Date
2020-03-24
Last Posted Date
2024-12-19
Lead Sponsor
Trans Tasman Radiation Oncology Group
Target Recruit Count
70
Registration Number
NCT04319783
Locations
🇦🇺

Icon Cancer Centre Epworth, Richmond, Victoria, Australia

🇦🇺

Peter MacCallum Cancer Centre, Bendigo, Bendigo, Victoria, Australia

🇸🇬

National Cancer Centre Singapore, Singapore, Singapore

and more 14 locations

Study of Radiation Therapy in Combination With Darolutamide + Degarelix in Intermediate Risk Prostate Cancer

First Posted Date
2019-11-25
Last Posted Date
2024-01-24
Lead Sponsor
University Health Network, Toronto
Target Recruit Count
208
Registration Number
NCT04176081
Locations
🇨🇦

UHN Princess Margaret Hospital, Toronto, Ontario, Canada

Darolutamide Augments Standard Therapy for Localised Very High-Risk Cancer of the Prostate

First Posted Date
2019-10-23
Last Posted Date
2023-07-28
Lead Sponsor
University of Sydney
Target Recruit Count
1100
Registration Number
NCT04136353
Locations
🇨🇦

Regional Health Authority B, Zone 2 Saint John Regional Hospital, Saint John, New Brunswick, Canada

🇨🇦

Ottawa Hospital Research Institute, Toronto, Ontario, Canada

🇨🇦

Odette Cancer Centre - Sunnybrook Hospital, Toronto, Ontario, Canada

and more 90 locations

INTREPId (INTermediate Risk Erection PreservatIon Trial)

First Posted Date
2019-07-18
Last Posted Date
2024-11-19
Lead Sponsor
Dana-Farber Cancer Institute
Target Recruit Count
234
Registration Number
NCT04025372
Locations
🇺🇸

Stamford Hospital, Stamford, Connecticut, United States

🇺🇸

Beth Israel Deaconness Medical Center, Boston, Massachusetts, United States

🇺🇸

Brigham and Women Hospital, Boston, Massachusetts, United States

and more 8 locations

Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial

First Posted Date
2019-03-18
Last Posted Date
2024-03-04
Lead Sponsor
OHSU Knight Cancer Institute
Target Recruit Count
2
Registration Number
NCT03878524
Locations
🇺🇸

OHSU Knight Cancer Institute, Portland, Oregon, United States

Study to Evaluate CCS1477 in Advanced Tumours

First Posted Date
2018-06-26
Last Posted Date
2024-07-17
Lead Sponsor
CellCentric Ltd.
Target Recruit Count
350
Registration Number
NCT03568656
Locations
🇺🇸

Dana-Farber Cancer Institute, Boston, Massachusetts, United States

🇺🇸

Thomas Jefferson University, Sidney Kimmel Cancer Center, Philadelphia, Pennsylvania, United States

🇺🇸

New York-Presbyterian Hospital/Weill Cornell Medical Center, New York, New York, United States

and more 19 locations

Prostate Cancer Biomarker Enrichment and Treatment Selection

First Posted Date
2017-12-28
Last Posted Date
2024-02-29
Lead Sponsor
Canadian Cancer Trials Group
Target Recruit Count
200
Registration Number
NCT03385655
Locations
🇨🇦

BCCA - Vancouver Cancer Centre, Vancouver, British Columbia, Canada

🇨🇦

Saskatoon Cancer Centre, Saskatoon, Saskatchewan, Canada

🇨🇦

Juravinski Cancer Centre at Hamilton Health Sciences, Hamilton, Ontario, Canada

and more 8 locations

Study on Androgen Receptor and Triple Negative Breast Cancer

First Posted Date
2017-12-26
Last Posted Date
2022-11-21
Lead Sponsor
UNICANCER
Target Recruit Count
94
Registration Number
NCT03383679
Locations
🇫🇷

Centre François Baclesse, Caen, France

© Copyright 2024. All Rights Reserved by MedPath